Congress of the International Society on Thrombosis and Haemostasis

Abstract Index

A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

P
P2X₁-induced activation of Ca²⁺ calmodulin leads to myosin light chain and ERK2 phosphorylation in human platelets
Toth-Zsamboki E., Oury C., De Vos R., Vermylen J., Hoylaerts M. F.

P2Y₁ signaling through Src tyrosine kinase in human platelets
Hardy A., Poole A. W.

P2Y₁₂ regulates platelet adhesion/activation, thrombus growth and thrombus stability in injured arteries
Andre P., LaRocca T., Vincent D., Delaney S. M., Deguzman F., Koller B., Phillips D. R., Conley P. B.

P2Y12 antagonists interact with agents that stimulate adenylate cyclase to inhibit calcium mobilization responses in platelets
Fox S. C., Behan M. W. H., Heptinstall S.

P38 MAP kinase is rapidly phosphorylated via agonist-specific pathways in human and dog platelets, but its activation is not causally linked to secretion
Johnson G. J., Leis L. A., Bender T.

PADA – fast and quantitative monitoring of blood platelet adhesiveness
Bucha E., Wiesenburg A., Schumann A., Nowak G.

PADA-HIT: A new POCT method for ultra-fast detection of HIT II antibodies
Nowak G., Schumann A., Wiesenburg A., Bucha E.

Paediatric haemophilia care: maximizing benefit, minimizing risk
Ljung R.

PAI-1, arteriosclerosis and coronary thrombosis: insights from genetically modified mice
Vaughan D.

PAR-1 (1–41) and SFLLRN independently propagate platelet activation
Ofosu F. A., Fenton J., Freedman J.

Paradoxical association between the 316 Trp to Ser beta 2-glycoprotein I (beta2GPI) polymorphism and antibeta2GPI antibodies
Nash M., Camilleri R. S., Liesner R., Mackie I. J., Machin S. J., Cohen H.

Paradoxical effect of Factor XIII replacement on clot initiation
Lovejoy A., Nakagawa P., Young G., Nugent D.

Paradoxical effect of unfractionated heparin in combination with streptokinase on arterial recanalization
Klement P., Vlasin M., Liao P., Rak J., Weitz J. I.

Partial results of the incidence of Thrombocytopenia Induced Heparin
Oliveira S. C., Rached R. A., Cavalheiro-Filho C., Chamone D. A. F.

Pathogen inactivation by ‘cascade iodination’
Shanbrom E.

Pathogenesis, diagnosis and therapy of TTP
Lämmle B.

Patients receiving long-term warfarin therapy prefer INR testing with capillary fingerstick over venous blood testing
Woods K., Schnurr T., Kinnon K., Crowther M. A., Mallory S., Douketis J. D.

Patients' valuation of outcomes after venous thromboembolism
Locadia M., Bossuyt P. M. M., Stalmeier P. F. M., Sprangers M. A. G., Bank I., Middeldorp S., Büller H. R., Prins M. H.

Patients with adverse pregnancy outcome have lower levels of protein Z and protein S compared to patients with normal pregnancy outcome
Mpaidas M. J., Ku D. H., Arkel Y. S., Lee M. J., Rebarber A., Saha M., Davidson B., Lockwood C. J.

Patients with localized and disseminated tumors have reduced but measurable levels of ADAMTS-13 von Willebrand factor cleaving protease)
Karimi M., Mannucci P. M., Mosalaei A., Canciani M. T., Peyvandi F.

Patients with mild hereditary bleeding disorders have normal thrombin generation (TGPPP) in platelet poor plasma
Quiroga T., Goycoolea M., Giesen P. L. A., Hemker H. C., Morales M., Muñoz B., Rodríguez S., Panes O., Martínez C., Pereira J., Mezzano D.

Patients with the post–thrombotic syndrome have worse disease severity and quality of life than patients with primary chronic venous disease
Kahn S. R., Kurz X., Lamping D. L., Berard A., Abenhaim L. A.

Patterns of cases and impact of venous thromboembolism (VTE) in a tertiary institution in Singapore: defying notions of VTE as a disorder of lower significance among Asians
Ng H., Quek S., Lee L. H.

Patterns of factor prophylaxis in the Canadian hemophilia A population
Blanchette P., Stain A. M., Rivard R., Israels S., Robinson S., Ali K., Walker I., Blanchette V.

PECAM-1 as a regulator of endothelial cell survival
Newman P.

PECAM-1 expression in adherent platelets differs from that of thrombi during human microvascular anastomosis
Olsson E., Sarlomo-Rikala M., Bohling T., Lassila R.

PECAM-1 inhibits LDL-signaling in platelets
Akkerman J. W. N., Gorter G., Van Rijn H. J. M., Relou I. A. M.

Pentoxifylline prevents spontaneous brain ischemia in stroke-prone rats
Mussoni L., Banfi C., Sironi L., Lodetti B., Guerrini U., Tremoli E.

Pepducin-based intervention of platelet signaling and systemic platelet activation
Covic L., Kuliopulos A.

Peptide decoys selected by phage display block in vitro and in vivo activity of a human anti-FVIII inhibitor
Villard S., Lacroix-Desmazes S., Piquer D., Grailly S., Benhida A., Kaveri S. V., Saint-Remy J. M., Granier C.

Peptides from the C-terminal regions of ADAMTS-13 specifically block cleavage of ultra-large von Willebrand factor multimers on the endothelial surface under flow
Bernardo A., Nolasco L., Ball C., Wang Y., Moake J., López J., Dong J.-F.

Percutaneous coronary interventions: is there a place for Argatroban
Lewis B.

Performance characteristics of the VIDAS and IL test d-dimer (d-d) assays as exclusionary tests for venous thromboembolism (VTE) after acute ischemic stroke (AIS)
Kelly J. A., Lewis R. R., Rudd A., Parmar K., Moody A., Hunt B. J.

Performance evaluation of the new CoaguChek^® PT.S-test on the CoaguChek^® S system
Plesch W., Klimpel P., Miller E., Fuller J., Newhart A., Jacobson A., Gutnik L., Dikkeschei L. D.

Performance of a new PT Calibrator
Merz M., Henckel T., Engelhardt W.

Pericellular plasmin induces smooth muscle cell anoikis
Meilhac O., Ho Tin Noe B., Michel J. B., Anglés-Cano E.

Peri-operative bleeding in patients with Pseudomyxoma peritonei appears to relate to trauma induced hypofibrinogenemia
Mainwaring J., Roy A., Needham J., Davies J., Mensah P., Moran B., Cecil T., Lewis H., Knight S.

Perioperative management of patients on oral anti-coagulants: a decision-analysis
Dunn A., Ho W., Wisnivesky J., Moore C., Mcginn T., Sacks H. S.

Perioperative management of patients on oral anti-coagulants: a systematic review
Dunn A. S., Turpie A. G. G.

Perioperative management with low molecular weight heparin (LMWH) of patients (pts) on long-term oral anticoagulant therapy (OAT) undergoing major surgery: a multicenter prospective observational study
Baudo F., Mostarda G., Molinotti M., Pengo V., Prisco D., Tiraferri E., on behalf of FCSA

Peri-procedure management of patients with heart valve replacements who require temporary interruption of warfarin therapy using low-molecular-weight heparin (enoxaparin)
Johnson J. A., Turpie A. G. G.

Persistence of the risk of venous thromboembolism (VTE) for at least four weeks after hip fracture surgery: evidence from the fondaparinux hip fracture surgery database
Eriksson B. I., Lassen M. R.

Persistent biochemical hypercoagulability and risk of death from cancer in middle-aged men
Miller G. J., Bauer K. A., Cooper J. A., Rosenberg R. D.

Perspectives on the role of rAHF-PFM in clinical practice
Collins P.

Perturbations in the blood T-cell repertoire of inhibitor-positive patients with severe hemophilia A
Misra N., Bayry J., Pashov A., Kaveri S. V., Kazatchkine M. D., Lacroix-Desmazes S.

PF4 and heparin form high molecular weight complexes that is central to the pathogenesis of Heparin-Induced Thrombocytopenia
Rauova L., Poncz M., Cines D. B., Mckenzie S. E., Reilly M. P., Arepally G. M., Sachais B. S., Mulder B.

Pharmacodynamic effects of the Low Molecular Weight Heparin (LMWH) tinzaparin in obese, hemodialysis, healthy human subjects on plasma tissue factor pathway inhibitor and nitric oxide
Mousa S.

Pharmacodynamic profile of Intimatan as an antithrombotic agent for venous thrombosis
Walenga J. M., Ma Q., Schultz C., Jeske W. P., Cardin A. D., Van Gorp C., Bakhos M.

Pharmacodynamics and pharmacokinetics of anti-Xa potency adjusted heparin derived oligosaccharides in nonhuman primates: implications in dosage optimization
Ma Q., Schultz C., Tobu M., Hoppensteadt D., Cornelli U., Fareed J.

Pharmacogenetics in the thrombolytic treatment of myocardial infarction: role of the FXIII V34L polymorphism
Roldán V., Corral J., Marín F., Rivera J., González-Conejero R., Pineda J., Miñano A., Acuña M. C., López F., Vicente V.

Pharmacokinetics and pharmacodynamics of LB30870, a novel oral low molecular weight direct thrombin inhibitor in healthy volunteers
Kim A., Park H. D., Kim J., Lee S. H., Kang H., Lee J. H.

Pharmacokinetics of BIBR 953 ZW, the active form of the oral direct thrombin inhibitor BIBR 1048, in patients undergoing hip replacement
Stangier J., Nehmiz G., Liesenfeld K. H., Holzschuh I., Hermansson K., Svaerd R., Dahl O. E., Ahnfelt L., Eriksson B. I.

Pharmacokinetics of functional von Willebrand Factor (VWF) with infusion of Koate-DVI^® in patients with von Willebrand's Disease (VWD)
Harrison J., Larson P., Burmeister Getz E., Powell J.

Pharmacokinetics of recombinant human FXIII in cynomolgus monkeys
Visich J. E., Cheong J., Zuckerman L. A., Ponce R., Pederson S., Dodds M. G., Vicini P., Rogge M.

Pharmacokinetics, pharmacodynamics and tolerability of single injections of activated recombinant FVII (rFVIIa, NovoSeven^®) in healthy Caucasian and Japanese subjects
Fridberg M. J., Hedner U., Roberts H., Erhardtsen E.

Pharmacological and cellular bases of some anti-thrombotic properties of extravirgin olive oil: studies on oleuropein and hydroxytyrosol
De Curtis A., Murzilli S., Rotondo S., Krauze-Brzosko K., Di Deo A., Del Boccio P., Cerletti C., Rotilio D., Donati M. B., Iacoviello L.

Phase I study of a novel recombinant human soluble thrombomodulin, ART-123
Moll S., Lindley C., Pescatore S., Morrison D., Tsuruta K., Mohri M., Serada M., Sata M., Shimizu H., Yamada K., White III G. C.

Phenotype of T cells in human abdominal aortic aneurysm
Galle C., Schandene L., Ferreira J., Wautrecht J. C., Dereume J. P., Goldman M.

Phenotypic sensitivity to activated protein C in healthy families: importance of genetic components and environmental factors in the Stanislas Cohort
Taralunga C., Guegen R., Wahl D., Visvikis S., Regnault V., Sass C., Siest G., Lecompte T.

Phenotypic thrombin generation: a composite view
Brummel K. E., Pouliot R. L., Mann K. G.

Phenotypic variation in real-time whole blood clot formation profiles in severe hemophilia. Response patterns following ex vivo addition of rFVIII and rFIX
Ingerslev J., Poulsen L. H., Sorensen B.

Phlebographic response and clinical outcome in the treatment of acute deep vein thrombosis
Breddin H., Kadziola Z., Scully M., Nakov R., Misselwitz F., Kakkar V. V.

Phosphoinositide 3-kinase beta (PI3Kb): a novel target for antithrombotic therapy
Yap C. L., Wright C. E., Kenche V., Schoenwaelder S. M., Anderson K. E., Yuan Y., Sturgeon S., Lu L., Hughan S. C., Kulkarni S., Jackson S. P.

Phospholipid composition of cell-derived microparticles determined by one-dimensional high-performance thin layer chromatography
Hoek F. J., Weerheim A. M., Kolb A. M., Sturk A., Nieuwland R.

Phospholipid-dependent impairment of the inhibitory properties of hirudin: the cause of false-positive assays for lupus anticoagulants (LAs)
Howard T. E., Channell C., Waddy S., Benson E., Duncan A.

Phosphorylation and expression of the extracellular domain of the platelet adhesion receptor, F11R (a.k.a. junctional adhesion molecule, JAM-1)
Babinska A., Kedees M. H., Sobocki T., Sobocka M. B., Athar H., Hussain M. M., Kornecki E., Ehrlich Y. H.

Phosphorylation of platelet proteins in hemodialysed patients is different than in control donors
Walkowiak B., Tanski W., Koziolkiewicz W.

Physical and functional interaction between PKCd and Fyn kinases in human platelets
Crosby D., Poole A. W.

Physicians' interpretation of ventilation-perfusion lung scans
Mac Gillavry M. R., Glas A. S., Lijmer J. G., Büller H. R., Bossuyt P. M. M.

Pilot introduction study of a needleless transfer device (BAXJECT) for reconstitution of Factor VIII concentrates for infusion
Leissinger C., Nuss R., Wulff K., Giambartolomei S., Raith C., Urbancik W., Spotts G.

PIP3 induces human platelet aggregation via an activation of a nonselective cation entry channel
Hassock S. R., Chen C.-S., Authi K. S.

Pitavastatin-induced thrombomodulin expression by endothelial cells acts via inhibition of small G proteins of the Rho family
Oida K., Kanehara H., Suzuki J., Masamura K., Miyamori I., Horie S., Ishii H.

Plasma 13-HODE: A novel and powerful predictor of cardiovascular disease (CVD) risk and severity
Buchanan M. R., Varghese R., Brister S. J.

Plasma adiponectin and the metabolic syndrome
Shand B. L., Scott R. S., Elder P. A., George P. M.

Plasma factor XIII activity, concentration and FXIII-A Val34Leu polymorphism in patients with myocardial infarction and/or coronary sclerosis
Bereczky Z., Czuriga I., Katona É., Kárpáti L., Édes I., Muszbek L.

Plasma fibrinogen, factor IIXa and other coronary heart disease risk factors in exercising and nonexercising men aged 30–45 years
Jones D. W., O'Donovan G., Kearney E. M.

Plasma fibrinolytic capacity and 4G/5G polymorphism of PAI-1 gene in heart and kidney transplant recipients with or without steroid immunosuppression
Sartori M. T., Spiezia L., Varvarikis C., Saggiorato G., Pellati D., Carraro G., Rigotti P., Marchini F., Gambino A., Girolami A.

Plasma glycocalicin level in diagnosis of the idiopathic thrombocytopenic purpura (ITP) in children
Ageyenkova E. V., Yakunina L. N., Lavrentyeva N. N., Vdovin V. V., Svirin P. V., Petrov V. V.

Plasma hemostatic markers in patients with malignancy: correlation with tumor progression and response to treatment
Sallah A. S., Sigounas G., Wan J., Nguyen N.

Plasma leptin is associated with hemostatic cardiovascular risk factors
Prasad U. K., Carter A. M., Freeman M. S., Grant P. J.

Plasma levels of soluble thrombomodulin and plasma thrombomodulin cofactor activity in the thrombin mediated activation of protein C: a comparative study
Öhlin A., Larsson K., Hansson M.

Plasma levels of the pro-inflammatory mediators TNF-alpha, IL-6 and IL-8 are risk factors for venous thrombotic disease
Reitsma P. H., Rosendaal F. R.

Plasma markers of hemostatic activation in patients with cancer and deep venous thrombosis
Sallah A. S., Wan J., Sigounas G., Vos P., Nguyen N.

Plasma P selectin must be measured in a citrated sample, not in serum
Caine G., Bareford D., Lip G. Y. H., Blann A.

Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation
Bastelica D., Mavri A., Morange P. E., Berthet B., Grino M., Juhan-Vague I., Alessi M. C.

Plasma procarboxypeptidase U is up-regulated in patients undergoing percutaneous intervention: effects of anticoagulant dosage of low molecular weight heparins
Florian-Kujawski M., Hoppensteadt D. A., Tobu M., Kereiakes D. J., Lewis B., Leya F., Fareed J.

Plasma tissue factor pathway inhibitor (TFPI) – A marker of severe coronary atherosclerosis
Mukherjee M., Joshi S. S., Shetty K. R.

Plasma-derived FXIII concentrate is as safe and effective as placenta-derived FXIII concentrate for the treatment of inherited FXIII deficiency
Castaman G., Tosetto A., Tagliaferri A., Rodeghiero F.

Plasmin-alpha2–anti-plasmin complex in diabetic and non diabetic patients with peripheral arterial occlusive disease
Gosk-Bireska I., Adamiec R., Wysokinski W. E.

Plasmin-mediated activation of platelets occurs through interaction with PAR-4
Quinton T., Kunapuli S. P.

Plasminogen activator inhibitor PAI-1 as a regulator of urokinase in angiogenesis
Noel A., Jost M., Maillard C., Devy L., Groot F., Foidart J. M.

Plasminogen activator inhibitor reversibly inhibits cell-surface single-chain but not two-chain urokinase associated plasminogen activation
Manchanda N., Burrus L. T.

Plasminogen activator inhibitor type I-deficient (PAI–/–) mice show an improved early host defense in E. coli peritonitis by a neutrophil-dependent mechanism
Weijer S., Florquin S., De Waard V., Lijnen H. R., Carmeliet P., Carmeliet P., Van Der Poll T.

Plasminogen activator inhibitor-1 (PAI-1) confers a survival advantage to breast cancer cells
Rehault S., Church F. C.

Plasminogen activator inhibitor-1 promotes fibrosarcoma cell migration by modifying cellular attachment to vitronectin via a vb 5 integrin
Urano T., Takahashi T., Suzuki K., Ihara H., Mogami H.

Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk
Juhan-Vague I., Alessi M-C., Mavri A., Morange P. E.

Plasminogen activators, plasminogen activator inhibitor-1 and D-dimer levels in gynecological cancer
Khalil R., Koh S. C. L., Lim F. K., Llancheran A., Chua S. E., Yuen W. K., Ng B. L., Loganath A., Choolani M.

Plasminogen activators: a feature of normal myeloid differentiation or leukemic transformation?
Chee Y-L., Culligan D. J., Bennett B., Greaves M.

Platelet activation and morphologic changes in hypertension
Nadar S., Kamath S., Blann A., Lip G. Y.

Platelet activation and platelet VASP phosphorylation in mice with streptozotocin-induced diabetes mellitus – association with endothelial dysfunction and reduced nitric oxide bioactivity
Schäfer A., Alp N. J., Cai S., Eigenthaler M., Bauersachs J., Walter U., Channon K. M.

Platelet activation causes a metalloprotease-mediated down-regulation of GlycoproteinVI
Stephens G., Jandrot-Perrus M., Villeval J. L., Clemetson K. J., Phillips D. R.

Platelet activity and circulating leukocyte-platelet aggregates can be markers of thrombotic and inflammatory processes in patients with coronary atherosclerosis
Bouriachkovskaia L. I., Rogova E. M., Uchitel I. A., Sumarokov A. B., Dovlatova N. L.

Platelet adhesion index and soluble E-selectin in the prediction of cardiovascular risk
Ciocoiu M., Colev-Luca V., Badescu L., Fratu C., Badescu M.

Platelet aggregates modulate the adhesion of breast adenocarcinoma cells (MDA-MB-231) to endothelial cells and their matrix in whole blood and under flow conditions
Gomes N., Vassy J., Legrand C., Fauvel-Lafeve F.

Platelet aggregation and ATP release in whole blood for diagnosis of bleeding disorders
Miller C. H., Nix B., Benson E., Abshire T. C.

Platelet and inflammatory changes induced by angioplasty and brachytherapy
Jeske W., Sundrani R., Saulters J., Lewis B. E., Steen L. H., Sochanski M., Grassman E. D., Leya F., Walenga J. M.

Platelet CD109: evidence for a transmembrane homologue on monocytes?
Jaikaran E., Garner S. F., Hernandez-Campo P., Mcbride S., Campbell K., Richards S. J., Hillmen P., Sutherland D. R., Ouwehand W. H.

Platelet CD40L and CD40 enhance tumor cell-induced coagulopathy and experimental metastasis
Ingersoll S., Amirkhosravi A., Amaya M., Meyer T. V., Desai H., Francis J. L.

Platelet depletion abolishes eosinophil recruitment to the lungs and tissue remodelling in an allergic asthma model in mice
Pitchford S., Momi S., Giannini S., Lever R., Riffo-Vasquez Y., Spina D., Page C. P., Gresele P.

Platelet deposition in the microvasculature of transplanted human liver provides an adhesive substrate for the recruitment of recipient leukocytes
Lalor P., Holden N., Adams D. H.

Platelet dysfunction in Icelandic teenagers. The bleeding assessment in teenagers (BAT) study
Gudmumdsdottir B. R., Onundarson P. T.

Platelet endothelial cell adhesion molecule-1 (PECAM-1) of platelets is cleaved under high shear stress
Naganuma Y., Satoh K., Yi Q., Asazuma N., Yatomi Y., Ozaki Y.

Platelet factor 4 (PF4) neutralizes heparan sulfate-dependent inactivation of factor Xa by preventing enzyme interaction with polysaccharide
Fiore M. M., Kakkar V. V.

Platelet factor 4 up-regulates protein C activation relative to TAFI activation
Mosnier L. O., Bouma B. N., Griffin J. H.

Platelet function and inflammatory markers in patients with type 1 diabetes with and without microvascular complications
Yngen M., Östenson C.-G., Hu H., Li N., Daleskog M., Johansson M.-C., Hillelson P., Hjemdahl P., Wallén N. H.

Platelet function peculiarities throughout childhood: a flow cytometric study from healthy premature new-borns up to 15-year-old-children
Hézard N., Potron G., Schlegel N., Amory C., Leroux B., Droullé C., Nguyen P.

Platelet function under aspirin, clopidogrel and both after ischemic stroke. A case-crossover study
Ruf A., Reiners S., Buggle CH., Lichy F., Becher H., Grau A. J.

Platelet glycoprotein Iba VNTR polymorphisms: association with thromboembolic diseases
Howard I. R., Lavender F. L., Gordge M., O'Shaughnessy D. F.

Platelet glycoprotein mRNAs are expressed in megakaryocytes and platelet like cells and are regulated during differentiation
Rieger S., Kunz F., Sunder-Plassmann R., Raith M., Mannhalter C.

Platelet glycoprotein VI has evolutionary conserved immunoglobulin domains, but a highly polymorphic stem and cytoplasmic domain
Watkins N. A., Rankin A., O'Connor M., Jennings N., Wilson E., Joutsi-Korhonen L., Mcbride S., Smethurst P. A., Harmer I. J., Farndale R. W., Ouwehand W. H.

Platelet GP VI can be new anti-platelet target for prevention of acute coronary syndrome
Goto S., Tamura N., Tanabe T., Handa S., Arai M., Kodama K., Takayama H.

Platelet inhibition by valsartan and valeryl 4-hydroxy valsartan: a possible missing link to explain benefits of angiotensin II receptor blockers in patients after acute vascular events
Serebruany V., Malinin A. I., Lowry D. R., Sane D. C., Webb R. L., Gottlieb S. O.

Platelet integrin a2 SNP 807C is a predictor of bleeding in Von Willebrand Disease (VWD) type 1
Kunicki T. J., Salomon D. R., Koziol J., Head S., Mondala T., Canciani M. T., Federici A. B.

Platelet interaction with stimulated or injured vessel wall
Wagner D.

Platelet mediated thrombin generation depends on F VIII and Factor IX in a complex way: evidences for the Cell-based model of hemostasis
Siegemund A., Siegemund T., Petros S., Scholz U., Engelmann L.

Platelet microparticles carry CD40 ligand and up-regulate TF and VEGF in endothelial and melanoma cells: possible role in angiogenesis and metastasis
Amirkhosravi A., Meyer T. V., Desai H., Sackel D., Amaya M., Biggerstaff J. P., Wehling J., Biddinger R.

Platelet P2Y12 inhibition decreases GPVI stimulated increases in thrombin generation on activated platelets
Kempton C. L., Roberts H. R., Monroe D. M.

Platelet proteomics
Maguire P. B., Fitzgerald D.

Platelet P-selectin and target organ damage in hypertension
Nadar S., Kamath S., Blann A., Lip G.

Platelet purified vascular endothelial growth factor-165 enhances tumor cell tissue factor expression and procoagulant activity
Siddiqui F., Desai H., Siddiqui T. F., Francis J. L.

Platelet receptor polymorphism HPA-1b and the G20210A mutation of the prothrombin-gene are risk determinants of vascular access thrombosis in hemodialysis patients
Zotz R., Steuer S., Zimmermann M., Koch M., Kleophas W., Gerhardt A., Grabensee B., Scharf R. E., Hollenbeck M.

Platelet receptor polymorphisms of glycoprotein (GP) Iba VNTR, GP IIb-IIIa (HPA–1), and GP Ia C807T and the risk of premature myocardial infarction
Zotz R. B., Teodoridis A., Müller C., Maruhn B.

Platelet recruitment in vivo to injured blood vessels is not prevented by GPIIb/IIIa antagonism
Melis E., Bonnefoy A., Daenens K., Yamamoto H., Vermylen J., Hoylaerts M. F.

Platelet resistance to aspirin is associated with increased membrane lipid cholesterol
Boncler M. A., Watala C.

Platelet responses mediated by venom snake metalloproteases (MP1 and MP3)
Modesto J. C. A., Ventura J. S., Schattner M., Chudzinski-Tavassi A. M.

Platelet sensitization is mediated by Apolipoprotein E Receptor 2
Relou I., Gorter G., Van Rijn H. J. M., Akkerman J. W. N., Lenting P. J.

Platelet septins and enhanced platelet function in SEPT5-deficient platelets
Martinez C., Savage B., Dent J., Ware J.

Platelet translocation on von Willebrand factor is inhibited by RGDS peptide at high shear rate
Vereycken-Holler V., Schoevaert D., Legendre P., Lindhout T., Baruch D.

Platelet von Willebrand factor antigen (VWF:Ag-i) in patients with mucocutaneous bleeding tendency and normal von Willebrand factor (VWF) plasma levels
Nadal Seillant M., Blanco A. N., Meschengieser S. S., Grosso S. H., Woods A. I., Lazzari M. A.

Platelet–erythrocyte interactions enhance GPIIbIIIa receptor activation and P-selectin expression during platelet recruitment. These effects are amplified in type I diabetic patients
Santos M. T., Vallés J., Cabrera-Espinós E., Martínez M., Ampuria-Blaso F. J., Moscardó A., Piñón M., Carmena R., Aznar J.

Platelet–leukocyte interactions in the presence of GPIIb-IIIa antagonists, and a combination of aspirin, dipyridamole and AR-C69931
Zhao L., Bath P. M. W., Heptinstall S.

Platelet–neutrophil interaction in Chernobyl wreckers accident liquidators
Rudko I., Argimbekova G., Kubatiev A. A.

Platelet, coagulation and endothelial markers in primary thrombocythaemia
Caine G., Bareford D., Karanth M., Blann A.

Platelet-associated Tissue Factor expression in patients with unstable coronary artery disease
Camera M., Frigerio M., Marenzi G. C., Salvioni A., Biglioli P., Tremoli E.

Platelet-associated Tissue Factor: modulation of cell surface expression by platelet agonists
Camera M., Brambilla M., Frigerio M., Cottell D., Rossi F., Maderna P., Toschi V., Parolari A., Biglioli P., Tremoli E.

Platelet-dependent alterations in fibrinolysis in the Quebec platelet disorder
Kahr W. H. A., Sheth P. M., Rivard G. E., Hayward C. P. M.

Platelet-dependent coagulation amplification – role of tissue factor, factor XI and factor XII
Ramström S., Lindahl T. L.

Platelet-derived growth factor receptor-alpha signaling is required for therapeutic angiogenesis induced by fibroblast growth factor-2
Tanii M., Maehara Y., Sueishi K., Tsutsumi N., Yonemitsu Y., Onimaru M.

Platelet-derived microparticle preparations for enzyme-linked immunoassay, and the high PDMP level detected in unstable angina patients
Ozeki Y., Uehata S., Tanaka A., Namba M., Kasuga N., Saito S., Kawarabayashi T., Nomura S.

Platelet-derived nitric oxide (NO) is suppressed by hyperhomocysteinemia: a possible prothrombotic effect
Gresele P., Lucarelli G., Mezzasoma A. M., Falcinelli E., Guglielmini G.

Platelet-leukocyte aggregation under shear stress: Differential involvement of selectins and integrins
Hu H., Varon D., Hjemdahl P., Savion N., Schulman S., Daleskog M., Johansson M. C., Li N.

Platelet-mediated vasodilatation factor activated by Zinc on diabetic rats
Badescu M., Ciocoiu M., Fratu C., Badescu L.

Platelets and fibrinogen are not required for embryonic development but have distinct roles for placentation
Isermann B., Zogg M., Weiler H.

Platelets endocytosis of HIV and S. aureus is enhanced by activation and occurs in specific compartment, site of subsequent degranulation
Cramer E., Boukour S., Youseffian T.

Platelets regulate protein C activity
Räike P.

Platelets regulate thrombin generation at their membrane surface through several unique activation-dependent mechanisms
Tracy P.

Platelets synthesize large amounts of PAI-1
Brogen H., Andersson M., Ulfhammer E., Lundholm C., Sverker J.

Platelets–coronary endothelium interaction: focus on L-arginine:NO system
Jakovljevic V., Mujovic V. M., Novokmet S. S., Djuric D. M.

PLC g-dependent GPIb signaling following platelet adhesion to von Willebrand factor through a pathway distinct from FcR g chain and FcgRIIA
Mangin P., Yuan Y., Eckly A., Freund M., Cazenave J-P., Gachet C., Jackson S. P., Lanza F.

PLCg2-independent activation of integrins by GPVI: involvement of PLCg1 and PI3-kinase
Suzuki-Inoue K., Frampton J., Watson S. P.

Point-of-care testing shows clinically relevant variation in the degree of inhibition of platelets by standard dose abciximab therapy during percutaneous coronary intervention
Ray M., Bett J.N., Cameron J., Wood P., Aroney C.

Polymorphisms in methylenetetrahydrofolate (MTHFR) gene and homocysteine (Hcy) levels in children
Annichino-Bizzacchi J. M., Alessio A. C.

Polymorphisms in the 3'-untranslated region of the TAFI mRNA modulate TAFI gene expression through control of mRNA stability
Maret D., Brien D. F., Franco R. F., Nesheim M. E., Koschinsky M. L., Boffa M. B.

Polymorphisms in the 5'UTR of the tissue factor (TF) gene are associated with differences in total and surface clotting activity and TF mRNA of endothelial cells
Terry C. M., Kling S. J., Hoidal J. R., Cheang K. I., Rodgers G. M.

Polymorphisms in the thrombomodulin gene as risk factors for myocardial infarction (HIFMECH study)
Konstantoulas C., Hawe E., Saut N., Yudkin J. S., Diminno G., Margaglione M., Hamsten A., Humphries S. E., Juhan-Vague I., Ireland H.

Polymorphisms of 5,10-methylenetetrahydrofolate reductase gene and risk of Korean acute leukemia
Oh D., Kim N. K., Lee J. H., Cho E. Y., Kim H. S., Park S., Yoon S. S., Lee J. A., Kim H. C., Kim C. S., Kim I. H., Ahn M. J., Kim S. H., Chi H. S.

Polymorphisms of platelet glycoproteins Ib-a and Ia/IIa: relationship with early arteriosclerosis and arterial thrombosis in patients with the antiphospholipid syndrome or with systemic lupus erythematosus
Tassies D., Jimenez S., García-Criado M. A., Espinosa G., Monteagudo J., Font J., Ordinas A., Reverter J. C.

Polymorphisms of the factor VII gene and ischemic stroke in young adults
Lopaciuk S., Carew J. A., Bykowska K., Pietrucha T., Kwiecinski H., Bauer K. A.

Polymorphisms of the interleukin 1-b gene, inflammatory and hemostatic response and the risk of premature myocardial infarction
Iacoviello L., Gattone M., Di Castelnuovo A., D'Orazio A., Amore C., Napoleone E., Lorenzet R., Colombo M., De Gaetano G., Giannuzzi P., Donati M. B.

Polypharmacologic actions of low-molecular-weight heparins: lessons from clinical trials
Fareed J., Bick R., Hoppensteadt D. A., Ma Q., Florian-Kujawski M. R., Bacher P.

Poor correlation between aPTT, anti-Xa levels and heparin dose in children receiving therapeutic doses of unfractionated heparin
Kuhle S., Eulmeskian P., Massicotte M. P., Vegh P., Persaud K., Kavanagh B., Mitchell L.

Population pharmacokinetics of the ReFacto coagulation factor VIII in clinical hemophilia patients with HIV
Lukas J. C., Anastasopoulou I., Katsarou O., Xiachopoulou P., Martin Suarez A., Zografidis T., Kotsi P., Karafoulidou A.

Population prevalence of atrial fibrillation and factors associated with use of warfarin
Tait R. C., O'Neill K. F., Murdoch D. L., Wallace I. W., Mcmahon A. D., Rumley A., Jackson J., Lowe G. D. O.

Population-based study of acquired hemophilia A
Collins P., Matsumoto T., Macartney N., Davies R., Lees S., Giddings J., Shima M.

Possible causes of variation in INR results in UK NEQAS EQA program for Near Patient Testing/Point of Care devices
Kitchen D. P., Kitchen S., Jennings I., Woods T. A. L., Preston F. E.

Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin
Kaaja R., Pettilä V.

Postpartum levels of activated TAFI (TAFIa) in patient plasmas
Neill E., Stewart R., Schneider M., Mousa H., Alfirevic Z., Toh C. H., Nesheim M. E.

Post-thrombotic complaints are not related to factor V Leiden mutation or elastic compression stockings: results of the MEGA Study
Tick L. W., Doggen C. J. M., Kramer M. H. H., Faber W. R., Rosendaal F. R.

Post-treatment of rats with simvastatin affords brain protection after focal ischemia as assessed by magnetic resonance imaging
Sironi L., Cimino M., Guerrini U., Lodetti B., Gelosa P., Paoletti R., Tremoli E.

Potential effect of recombinant factor VIIa in ex vivo reversal of pentasaccharide induced anticoagulation
Sorensen B., Ingerslev J.

Potential reversal agents for the long-acting pentasaccharide idraparinux
Van Amsterdam R. G. M., Buiting M. T., Vogel G. M. T., Princen T. W. M., Remijn J. A., Meuleman D. G., Lensing A. W. A.

Potentiation of aggregation through the stimulation of platelet P2X1 receptors
Erhardt J., Pillarisetti K., Toomey J.

Pravastatin modulates the cytokine-induced endothelial expression of PGE2: A novel anti-inflammatory mechanism of cholesterol-lowering drugs
Orbe J., Roncal C., Monasterio A., Belzunce M., Páramo J. A.

Precision of INR (International Normalized Ratio) measurement using laboratory and point-of-care assays: Understanding the impact of system influence on patient management
Laduca F., Gunneman T., Ruybalid R. L., Jacobson A., Zucker M.

Precision of the PFA-100 platelet function analyzer: A practical and cost effective method of quality control (QC) for the clinical coagulation laboratory
Hammouda W., Schiavone A.

Preclinical safety assessment of photochemically treated platelets: no toxicologically relevant effects with large multiples of the clinical exposure
Ciaravino V., Cimino G., Mccullough T.

Preconceptional and gestational enoxaparin regimes adjusted to fertility program to prevent preclinical, embryonic and fetal loss in women with Recurrent Pregnancy Loss (RPL) and thrombophilia
Sarto A., Martinez M., Falco A., Smaltino V., Marazzi A., Paganini A., Capmany C., Pasqualini S.

Preconceptional, gestational and puerperal low anti-annexin A5 antibody levels in women who develop pre-eclampsia
Van Heerde W., Steegers-Theunissen R. P. M., Van Der Linden I., Roes E., Peer N., Lemmens W., Steegers E. A. P.

Predicting the risk of recurrence of venous thromboembolism – genetic determinants and elevated coagulation factors
Kyrle P.

Predicting the risk of thromboembolic recurrences: the value of D-dimer
Palareti G.

Prediction and prevention of thrombosis during pregnancy and oestrogen use
Ivey L. M., Staton J. M., Maslen K. E., Sayer M. S., Hughes Q. W., Barden A. E., Singh R., Beilin L. J., Baker R. I.

Prediction of the organ dysfunctions by coagulation/fibrinolysis molecular markers at the beginning of sepsis
Iba T., Kidokoro A., Fukunaga M., Sugiyama K.

Predictive factors of cancer discovery after deep-vein thrombosis: a 8-years follow-up study
Laporte S., Mismetti P., Quenet S., Buchmuller-Cordier A., Chabaud S., Decousus H., Tardy B.

Predictors of recurrent thrombo-embolic events in 153 infants and children with cerebral sinovenous thrombosis: a national population based study
Deveber G., Chan A. K., Sofronas M., STROKE STUDY GROUP CANADA

Premature atherosclerosis in adult growth hormone deficiency: interaction of fibrinolytic and metabolic factors
Milijic P., Milijic D., Popovic V., Colovic M.

Prenatal diagnosis of dysprothrombinemia in an Iranian family
Hong S. H., Lotfi V., Peyvandi P., Lak M., Zeinali S.

Prenatal diagnosis of hemophilia A in the only governmental center for prenatal diagnosis in IRAN
Zeinali S., Zeinali M.

Preparation of prothrombin complex concentrate (PCC) at intermediate scale: first experience in Argentina
Bernardi M. E., Bermudez M. C., Hurvitz A., Oviedo S. A., Moya C., Zingale G., Vitali M. S., Zarzur J. A.

Preparation of special proteome chip and the application in primary screening of antigens of clotting factors of clinical plasma specimens
Xiaoyu L., Zhou L.

Preparations of beta-2 glycoprotein I contain plasma kallikrein
Jones D. W., Gallimore M. J., Harris S. L., Winter M.

Prescribing anticoagulant prophylaxis in patients with hematological or solid tumor malignancies and central vein catheters: a nationwide survey
Van Rooden C. J., Kettenis I. M. J., Monraats P. S., Rosendaal F. R., Huisman M. V.

Present status of hemorrhargic disease of newborn and young infants resulting from vitamin K deficiency in Japan
Shirahata A., Shirakawa Y., Urano H.

Pre-surgical reversal of warfarin using recombinant activated factor VII (rFVIIa) in a pediatric patient with prosthetic heart valves
Wu J. K., Riding K. H., Duncan W. J.

Prethrombotic biological markers in congenital thrombophilic patients. Preliminary results of a randomized long-term secondary prophylaxis study using warfarin and comparing two INR target ranges
Borg J., Le Cam-Duchez V., Cailleux N., Gandelin C., Fretigny M., Hellot M.-F., Levesque H.

Prevalence and impact on clinical outcome of concomitant peripheral arterial disease (PAD) in patients with coronary and cerebrovascular diseases: the Pathos project
Agnelli G., Cimminiello C., Meneghetti G., Urbinati S.

Prevalence of activated protein C – resistance (APC-R) in patients with thromboembolic events: the first report from Iran
Latifzadeh S., Entezari V., Shashaani T., Jazebi M.

Prevalence of anti-Erythropoietin antibodies in end stage renal disease patients treated with recombinant Erythropoietin
Fareed J., Walenga J. M., Tobu M., Iqbal O., Hoppensteadt D., Messmore H. L., Chadha M., Choudhary S., Bansal V. K., Moghaddam M.

Prevalence of Arg 506 and Arg 306 mutations of the factor V gene in Thai blood donors
Sasanakul W., Jarutwachirakul W., Rurgkhum S., Kadegasem P., Tardtong P., Chuansumrit A.

Prevalence of circulating procoagulant microparticles in allogeneic stem cell transplantation (alloSCT) for hemato-oncological malignancies
Inbal A., Dardik R., Sela B.-A., Eskaraev R., Nagler A.

Prevalence of factor V Leiden and FV HR2 haplotypes as risk factors for deep vein thrombosis: a study from north India
Das R., Garewal G., Ahluwalia J., Varma S.

Prevalence of Factor V Leiden and Prothrombin G20210A Mutations in Malaysian patients with thromboembolic disorders
Thiruchelvam A., Ayob Y.

Prevalence of factor V Leiden, FII G20210A, FXIII Val34Leu and MTHFR C677T polymorphisms in cancer patients with and without venous thrombosis
Ramacciotti E., Wolosker N., Leão P. P., Zeratti E. A., Gusson P. R., Del Giglio A., Franco R. F.

Prevalence of factor V Leiden, MTHFR C677T and prothrombin G20210A mutations in Lebanese thalassemia intermedia patients
Taher A.

Prevalence of haemostatic abnormalities in women with 3 or more implantation failures after in vitro fertilization
Grandone E., Colaizzo D., Vecchione G., Cappucci F., Lo Bue A., D'Angelo F., Cittadini E., Di Minno G., Margaglione M.

Prevalence of haemostatic and fibrinolytic abnormalities in women with unexplained embryofetal losses and vascular obstetric complications
Sanchez-Luceros A., Meschengieser S. S., Casais P., Salviú M. J., Alberto M. F., Bermejo E., Nadal M. V., Gennari L., Lazzari M. A.

Prevalence of hyperhomocysteinemia among aluminum industry workers
Mansoor M., Kristensen O., Hervig T., Stakkestad A., Berge T., Drabløs P. A., Rolfsen S.

Prevalence of methylenetetrahydrofolatereductase (MTHFR) gene polymorphism (C677T) in the Moroccan population
Mathonnet F., Nadifi S., Le Moal V., Moynard D., Giudicelli Y.

Prevalence of thrombophilic genetic mutations in patients undergoing thrombotic events while on oral anticoagulants: a case-control study
Taliani M. R., Castori L., Agnelli G., Nenci G. G., Gresele P.

Prevention of stroke in atrial fibrillation - can we do better?
Lip Y.H.

Prevention of thromboemboli by enhancing fibrinolysis: a possible therapeutic mechanism of action for Dextran-40
Jones C. I., Payne D. A., Hayes P. D., Bell P. R. F., Thompson M., Goodall A. H.

Prevention of venous thromboembolism in orthopedic trauma patients receiving heparin thromboprophylaxis – a substudy analysis of autopsy-confirmed fatal pulmonary embolism
Haas S., Lassen M. R., Wolf H., Brom J., Weidinger G., Fareed J.

Prevention of wine consumption on thrombosis but not on atherosclerosis in ApoE^-/- mice
Bal dit Sollier C., Soulat T., Philippe C., Berge N., Brezillon C., Rabot S., Drouet L.

Primordial role of the P2Y12 ADP receptor in different phases of platelet–collagen interactions
Maurice P., Lebos C., Arbeille B., Frojmovic M., Legrand C., Fauvel-Lafeve F.

Prions are removed from equipment used in the production of plasma derivatives by standard cleaning procedures
Gröner A., Boose J. A.

Pro-atherogenic role for IgG antioxidised-low-density-lipoprotein-beta-2-glycoprotein-I complex in primary antiphospholipid syndrome
Ames P. R. J., Delgado-Alves J., Lopez D., Lopez L., Margarita A., Matsuura E., Iannaccone L., Brancaccio V.

Probabilistic modeling of population-based epidemiology and treatment modalities to determine unconstrained factor VIII demand
Larson P. J., Stonebraker J. S., Amand R. E., Bauman M. V., Nagle A. J.

Procoagulant activity of neonatal platelets
Israels S. J., McMillan-Ward E. M.

Procoagulant changes in human macrophages induced by environmental microparticles [PM₁₀]: a possible pathogenetic mechanism in cardiovascular disease
Morrison E. R., Gilmour P. S., Donaldson K., Macnee W., Vickers M. A., Ford I., Greaves M.

Procoagulant effects of raloxifene in postmenopausal women
Franco R. F., Baggio M. S., Sala M. M., De Sá M. F. S., Azevedo G. D.

Procoagulant factors and the risk of myocardial infraction in young women
Tanis B., Helmerhorst F. M., Algra A., Van Der Graaf Y., Rosendaal F. R.

Procoagulant phospholipid in blood normally associates mainly with cells or aggregates larger than microparticles or platelets
Exner T., Joseph J., Low J., Connor D., Ma D.

Procoagulant surface expression on activated human platelets persists despite increased aminophospholipid translocase activity
Leung R., Wang H., Bang K.W.A., FreeDman J., RAnd M.L.

Profile of mutations in a UK hemophilia A patient population
Western A., Nesbitt I. M., Makris M., Goodeve A. C.

Prognostic value of activated protein C levels in patients with severe sepsis
Liaw P., Esmon C. T., Kahnamoui K., Schmidt S., Kahnamoui S., Ferrell G., Beaudin S., Weitz J., Loeb M., Cook D.

Prognostic value of selected genetic variants of platelet glycoprotein receptors in prediction of thrombotic events after percutaneous coronary interventions
Sydor W. J., Dudek D., Sanak M., Dubiel J., Musial J.

Projection parameters for usage of blood products in Singapore General Hospital
Chin K. W., Chua M. L., Ho L. P., Tien S. L.

Prolongation of the aPTT is far inferior to thrombin generation as an indicator of the heparin anti-coagulant effect
Hemker H. C.

Prolonged APTT children undergoing elective tonsillectomy
Montaruli B., Agnes C., De Vicaris A., Foli C., Vaccarino A., Rus C., Saitta M., Gaido F., Bazzan M.

Prolonged platelets preservation by transient metabolic suppression
Alamdary Badlou B., Smid W. M., Akkerman J. W. N.

Prolonged prophylaxis against VTE with enoxaparin in patients undergoing surgery for malignancy: 1-year survival study
Bergqvist D., Agnelli G., Cohen A. T., Nilsson P. E., Le Moigne-Amrani A., Dietrich-Neto F.

Prolonged prophylaxis with the low molecular weight heparin certoparin reduces the rate of venous thromboembolism after orthopedic surgery
Kolb G., Bodamer I., Galster H., Grambach K., Koudela K., Eisele R. R., Becker C., Paal V., Spannagel U., Brom J., Weidinger G.

Prolonged thromboprophylaxis with low molecular weight heparin (dalteparin) after major abdominal surgery: the FAME study
Rasmussen M. S., Jorgensen L. N., Wille-Jørgensen P., Nielsen J. D., Soemod L., Harvald T., Horn A., Mohn A. C., Pilsgaard B., Olsen B.

Prolonged thromboprophylaxis with low molecular weight heparin (tinzaparin) following major general surgery primarily for cancer: An individual patient data meta-analysis
Jorgensen L. N., Lausen I., Rasmussen M. S., Wille-Jorgensen P., Bergqvist D., Prism Trial Investigators

Promotion of thrombin generation at low FVIII concentrations by FIXa
Mcintosh J. H., Owens D., Lee C. A., Raut S., Barrowcliffe T. W.

Prophylactic factor replacement therapy in children with severe factor X deficiency
Chandra D., Williams M., Marshall D.

Prophylactic treatment of afibrinogenemia with the fibrinogen concentrate Haemocomplettan^®
Siegmund B., Richter H., Pollmann H.

Prophylactic warfarin in clinical practice. Treatment intensity when warfarin is used to prevent VTE after major joint surgery: findings from the Global Orthopedic Registry (GLORY)
Gallus A., Friedman R., Cushner F., Anderson F., White K., Weiss D.

Prophylaxis against bleeding with a factor VIII-von Willebrand factor concentrate in hemophilia A with high titer inhibitor
Schulman S., Holmström M., Ågren A.

Prophylaxis against venous thromboembolism
Borley J., Kakkar A. K.

Prophylaxis for long distance travel
Baker R.

Prophylaxis in medical patients
Cohen A.

Prophylaxis of deep vein thrombosis after lower extremity amputation: comparison of low molecular weight heparin with unfractionated heparin
Lastoria S., Rollo H. A., Giannini M., Moura R., Yoshida W. B., Maffei F. H. A.

Prophylaxis of main obstetric complications in pregnant women with anti-phospholipid syndrome and genetic forms of thrombophilia
Makatsaria A., Bitsadze V. O., Baimuradova S. M., Dolgushina N. V.

Prophylaxis of recurrent thromboembolism in a patient with a history of heparin-induced thrombocytopenia with thrombosis, anti-lepirudin antibodies after Bjork-Shiley aortic valve implantation using fondaparinux
Harenberg J., Jörg I., Fenyvesi T., Hagedorn A., Giese C., Trager I.

Prophylaxis Study in Inhibitor Patients
Leissinger C.

Proposed mechanisms of thrombolytic action of the medicinal leech saliva
Zavalova L., Baskova I. P., Basanova A. V.

PROS1 mutations that introduce a premature termination codon explain protein S deficiency by nonsense-mediated mRNA decay
Muñoz X., Espinosa-Parrilla Y., Hurtado B., Navarro G., Domènech P., Pérez-Riba M., Sala N.

PROSIT: functional analysis of identified PROS1gene mutations
Razzari C., Simmonds R. E., Biguzzi E., Castaman G., Margaglione M., Faioni (for Prosit) E. M., Lane D. A.

Prospective assessment of the diagnostic accuracy of the ISTH criteria for the diagnosis of DIC
Bakhtiari K., Meijers J. C., De Jonge E., Levi M.

Prospective cohort study of paediatric venous thrombosis
Monagle P., Newall F., Crock C., Savoia H. F., Campbell J., Wallace T.

Prospective evaluation of t-PA/PAI-1 complex predicting myocardial infarction in controls included in the SHEEP study
Nordenhem A., Sten-Linder M., Leander K., Hallqvist J., Defaire U., Wiman B.

Prospective study of the risk factors for the development of post–thrombotic syndrome after proximal deep vein thrombosis
Reus S., Lopez I., Botella C., Lucas J., Manso M., Marco P.

Prospective study on the diagnosis of HIT at King's College Hospital
Arya R.

Prostacyclin protects basal and nitric oxide-induced megakaryocytes apoptosis
Negrotto S., Pozner R. G., D'Atri L. P., Lazzari M. A., Gomez R. M., Maugeri N., Schattner M.

Protease-activated receptors in vascular biology
Coughlin S.

Protease-nexin-1 inhibits plasminogen activation-induced apoptosis of adherent cells
Rossignol P., Vranckx R., Bouton M. C., Meilhac O., Guillin M. C., Michel J. B., Anglès-Cano E.

Proteases derived from Ficus carica activate human factor X
Richter G., Schwarz H. P., Turecek P. L.

Protection of a chimeric antihuman tissue factor monoclonal antibody against tissue factor-induced acute thrombosis in mice
Wen J. H., Han K. P., Negrouk G., Wong H. C., Jiao J. A.

Protection of thrombosis by glyproline peptide Semax
Cherkasova K.

Protein C activation and possible use in different disease states - Multi-organ failure and underlying thrombocytopenia
Carcillo J.

Protein C activation and possible use in different disease states - Necrotizing enterocolitis
Peters M.

Protein C activation and possible use in different disease states - Neonatal sepsis
Veldman A.

Protein C activation and possible use in different disease states - Protein C activation
Smith O.

Protein C levels in critically ill ICU patients: differences seen between patients with and without sepsis
Gosselin R. C., Roach D. M., King J. H., Larkin E. C., Alberston T., Owings J. T.

Protein C promoter polymorphisms are potential additional risk factors for cerebral venous thrombosis
Le Cam-Duchez V., Fretigny M., Bagan-Triquenot A., Chretien M.-H., Mihout B., Borg J.-Y.

Protein C, S and antithrombin III levels in patients with acute mechanical valve thrombosis
Ayaz S., Yilmaz S., Tutun U., Ulus T.

Protein S confers neuronal protection during ischemic/hypoxic injury in mice
Liu D., Guo H., Griffin J. H., Fernandez J. A., Zlokovic B. V.

Protein Z
Broze G.

Protein Z levels in acute coronary syndromes
Sofi F., Fedi S., Tellini I., Cesari F., Brogi D., Marcucci R., Prisco D., Pepe G., Abbate R., Gensini G. F.

Protein Z-dependent protease inhibitor (ZPI) deficiency: a new thrombotic risk factor?
Van De Water N., Ashton F., Tan T., Day T., O'Grady A., Browett P., Ockelford P., Harper P.

Protein–protein interaction between Fli-1 and GATA-1 mediates synergistic expression of megakaryocyte-specific genes through cooperative DNA-binding
Eisbacher M., Holmes M. L., Hogg P. J., Newton A., Khachigian L. M., Crossley M., Chong B. H.

Proteoglycans dock kininogens to cells and regulate generate bradykinin generation
Renné T., Müller-Esterl W., Walter U.

Proteolysis of tissue factor pathway inhibitor-1 on circulating microparticles after thrombolysis in acute myocardial infarction contributes to thrombin formation
Steppich B., Stratz C., Rutz T., Schömig A., Neumann F.-J., Ott I.

Proteolytic pattern in advanced atherosclerotic human lesions: relation to vascular bed, plaque features, and cardiovascular risk factors
Orbe J., Fernandez L., Belzunce M., Monasterio A., Rodriguez J. A., Páramo J. A.

Proteomic analysis of proteins secreted by platelets
Coppinger J., Cagney G., Cahill D. J., Fitzgerald D. J., Maguire P. B.

Proteomic identification of tissue factor regulatory components in blood monocytes
Wu H., Jin M., Marsh C.

Prothrombin mutation G20210A, and not factor V Leiden, is a significant risk factor for cerebral venous thrombosis in 27 Brazilian patients
Rocha L., Rodrigues C. A., Morelli V. M., Noguti M. A. E., Alvares V. A. C., Real M. M. D. V., de Leon C. M. M. P., Perin A. D., Lourenço D. M.

P-Selectin deficiency results in impaired thrombus formation and frequent embolization in mouse model of carotid artery thrombosis
Jirouskova M., Chereshnev I., Vaanaanen H., Coller B. S., Smyth S. S.

P-selectin polymorphisms: their relationship to soluble P-selectin levels and cardiovascular risk
Carter A. M., Anagnostopoulou K., Mansfield M. W., Grant P. J.

P-selectin-dependent lung colonization of melanoma cells is targeted by heparin treatment
Ludwig R., Schultz J. E., Podda M., Zollner T. M., Boehncke W. H., Tandi C., Jaeger J. E., Zacharski L. R., Kaufmann R., Gille J.

Pseudogene coamplification mimicking a 14-bp deletion mutation in exon 5 of plasminogen gene: a methodological study
Sartori M. T., Saggiorato G., Pellati D., Dal Bello F., Granzotto M., Spiezia L., Lombardi A. M., Girolami A.

Psychologic impact of thrombophilia screening in asymptomatic relatives of carriers of prothrombotic mutations
Torrano-Masetti L., Rizzatti E. G., Oliveira L. C. O., Inácio R. A., Santos M. A., Franco R. F.

Psychosocial aspects of inherited bleeding disorders among Iranian patients
Nafissi Z., Zeinali S.

PT20210 and Factor V Leiden mutations are not protective against bleeding during treatment with vitamin K antagonists
van der Heijden J.

PTS after calf vein thrombosis (CVT): a 10-year follow-up
Eisele R., Langhoff F., Kinzl L.

Pulmonary embolism in liver transplant setting associated with the use of solvent detergent plasma
Jain N., Kirschbaum N., Gaines A., Coignard B., Jarvis W., Silverman T.

Purification and formulation of a dual viral-inactivated fibrinogen concentrate for use in a fibrin sealant
Clemmitt R., Archer R., Christian K., Kingsland S., Feldman P. A.

Purification and identification of coagulation factor IX-activating enzyme on the erythrocyte membranes
Iwata H., Kaibara M., Dohmae N., Takio K.